Find Clinical Trial

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

IndicationSolid tumors
SponsorInstitut de Recherches Internationales Servier
Active substance/
Medical device

AG-120

Active Substance CodeAG-120
Protocol CodeAG120-C-002
EudraCT Code2014-000064-18
NCT CodeNCT02073994


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility